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Objective: Prolonged eosinophil survival plays an important role in the pathogenesis of 
Churg-Strauss syndrome (CSS); however, its detailed molecular mechanism is still 
unclear.  Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and 
its receptors are expressed on a variety of cells including eosinophils.  In this study, we 
examined TRAIL receptor expression on eosinophils in CSS.  Methods: We assessed 
TRAIL receptor expression on eosinophils in healthy volunteers and in patients 
suffering from CSS, asthma, and hypereosinophilia due to parasitic infection.  In 
addition, we compared TRAIL-induced eosinophil apoptosis between CSS and asthma 
patients.  We suppressed TRAIL receptor 3 expression through RNA interference and 
investigated the resultant effect on the TRAIL-induced apoptosis of eosinophils from 
CSS patients.  Results: The expression level of TRAIL receptor 3, a decoy receptor 
that acts as an antiapoptotic receptor, on eosinophils from CSS patients was 
significantly higher than that in the other subjects.  In CSS, serum TRAIL receptor 3 
levels revealed significant positive correlations with peripheral eosinophil counts.  
Expression of TRAIL receptor 3 by tissue-infiltrating eosinophils was observed 
immunohistochemically in the CSS patients.  Peripheral T cells expressed TRAIL on 
their surface.  In comparison with asthma, the percentage of recombinant TRAIL and 
autologous T cell-induced eosinophil apoptosis and the active eosinophil caspase-3 level 
in CSS were significantly lower.  Suppression of TRAIL receptor 3 expression through 
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RNA interference significantly increased the recombinant TRAIL-induced eosinophil 
apoptosis in the CSS patients.  Conclusion: We observed increased TRAIL receptor 3 
expression on eosinophils in the CSS patients.  Increased TRAIL receptor 3 expression 
on eosinophils might be involved in the molecular pathogenesis of CSS eosinophilia. 
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Introduction 
Churg-Strauss syndrome (CSS) is a multiorgan disease with eosinophilia in tissues and 
blood (1). Eosinophils can secrete a number of cytokines (1-3), such as eosinophil major 
basic protein (MBP) and eosinophil-derived neurotoxin (EDN) (4), these cytokines play 
a pivotal role in the pathogenesis of disorders with eosinophilia.   They are thought to 
cause tissue damage due to their cytotoxic activities (5;6).  Thus, marked eosinophilia 
in tissues and blood due to prolonged eosinophil survival (7) seems to be implicated in 
the pathogenesis of CSS (1;2).  In this regard, impaired apoptosis of eosinophils has 
been reported (8-10) ; however, the detailed mechanism of eosinophilia in CSS has not 
been fully elucidated.   
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of 
the TNF superfamily (11).  TRAIL can interact with 2 death receptors (DRs), namely, 
TRAIL receptor 1 (DR4) (12) and TRAIL receptor2(DR5) (13), and 2 decoy receptors 
(DcRs), namely, TRAIL receptor 3 (DcR1) (12;14;15) and TRAIL receptor4(DcR2) 
(16;17).  TRAIL receptors 1 and 2 contain an intracellular motif called the “death 
domain” that subsequently activates cysteinyl aspartic acid protease (caspase)-8 (12;13).  
Active caspase-8 transmits its proapoptotic activity to executioner caspases such as 
caspase-3 or caspase-7 (12;13;18;19).  In contrast, TRAIL receptors 3 and 4 have 
either truncated or missing intracellular domains and are unable to transduce the death 
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signal (13;15;17); this suggests that these receptors may compete for ligand-binding and 
act as antiapoptotic receptors (20).  These receptors have become known as decoy 
receptors and are thought to be critical to the regulation of TRAIL signaling by 
competing for TRAIL binding sites (21).  
?????? ????????? ??? ?????????????????????????? ???????? ???????????? ?????????????? ???
???????????????????? ???????????????????? ??? ????????? ???????????????????? ????? ????
???????????????????????????????????????????????????????? ? ??????????????????????????????
???????????????????????? ?However, the role of TRAIL in CSS remains unknown.  In 
this study, we investigated the TRAIL receptors on eosinophils and the apoptosis caused 
by TRAIL-induced eosinophils using samples from patients suffering from CSS and 
asthma.  A difference in the expression pattern of TRAIL receptors between CSS 
patients and asthma patients has been discovered.  In addition, we have observed that 
eosinophil apoptosis in CSS patients induced by recombinant TRAIL and autologous T 
cells that express TRAIL on the surface was attenuated by the increased expression of 
TRAIL receptor 3 on the eosinophils.  Glucocorticoids are capable of modulating the 
expressions of TRAIL receptor 3 in eosinophils.  It is suggested that TRAIL is 
potentially involved in the pathogenesis of eosinophilia in CSS. 
Materials and Methods 
Patients 
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This study was reviewed and approved by the Kagoshima University Faculty of 
Medicine Committee on Human Research.  We investigated 34 patients (males, 14; 
females, 20) with CSS who were admitted to the Division of Respiratory Medicine, 
Respiratory and Stress Care Center, Kagoshima University Hospital from 1995 to 2005 
for the diagnosis and treatment of CSS.  The mean age of the patients was 56.3 ± 19.2 
years (mean ± standard deviation).  All patients were initially diagnosed with CSS 
because of the presence of asthma and eosinophilia; the diagnosis of CSS was 
confirmed by observing the existence of eosinophilic vasculitis in skin or nerve biopsy.  
Clinical features of the CSS patients upon admission are shown in Table 1.  For 
comparison, we also investigated 29 patients (male, 13; female, 16; mean age, 58.9 ± 
15.3 years) with asthma.  All asthma patients were fresh cases and did not receive any 
medication.  We examined 11 patients (male, 5; female, 6; mean age, 57.3 ± 23.1 
years) with hypereosinophilia (HES) due to parasitic infection before the start of therapy.  
Out of these, 3 patients were infected with Ascaris suum, 2 with Strongyloides 
stercoralis, 4 with Paragonimus westermani, and 2 with Dirofilaria immitis.  We also 
recruited 14 healthy volunteers (male, 7; female, 7; mean age, 58.9 ± 13.1 years).  All 
participants provided written consent to participate in the study.  The classification of 
CSS was made according to the 1990 edition of CSS published by the American College 
of Rheumatology (26) ; all patients with CSS fulfilled more than 5 criteria outlined in 
the publication.  We excluded patients with rheumatoid arthritis, diabetes mellitus, 
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acute or chronic liver disease, and immunological abnormalities that predispose to 
opportunistic infection.    
Preparation of eosinophils and T cells 
Human eosinophils were obtained from heparinized venous blood of the CSS and 
asthma patients before they underwent therapy.  Heparinized venous blood was mixed 
with a quarter volume of 2% dextran solution (Sigma-Aldrich Corp., St Louis, MO, 
USA) to precipitate red blood cells.  After incubation for 30 min at room temperature, 
the leukocyte-rich plasma was laid onto Histopaque (Sigma-Aldrich Corp., St Louis, 
MO, USA) and centrifuged at 800 ×g for 20 min at room temperature.  Granulocytes 
were separated from erythrocytes by lysis in 0.2% NaCl and washed in 
phosphate-buffered saline (PBS) 3 times at 4°C; next, eosinophils were isolated by 
negative selection using magnetic beads (Eosinophil Isolation Kit; Miltenyi Biotec 
GmbH, Bergisch, Germany) according to the manufacturer’s protocol.  Eosinophils 
were resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium containing 
10% fetal calf serum (FCS) and streptomycin/penicillin (the complete medium).  The 
purity of eosinophils was more than 99% by morphological examination after staining 
with Diff-Quick (Wako, Tokyo, Japan).  
Moreover, peripheral blood mononuclear cells (PBMCs) were separated from 
heparinized venous blood of CSS and asthma patients by Histopaque gradient 
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centrifugation as described previously (22).  T cells were isolated by negative selection 
using the abovementioned magnetic beads according to the manufacturer’s protocol.  
The purity of T cells was observed to be more than 95% by fluorescence-activated cell 
sorting (FACS) analysis.  
Flow cytometry analysis  
To detect the expression of TRAIL receptors on eosinophils, 5 × 105 cells were 
collected after incubation in various states.  The cells were washed with PBS 3 times 
and then incubated with human serum (pooled sample from healthy volunteers) for 10 
min; subsequently, they were further incubated with biotinylated goat antihuman 
TRAIL receptor 1, 2, 3, and 4 antibodies (R&D Systems, Minneapolis, MN, USA) for 
20 min at 4°C.  After washing 3 times with PBS, the cells were incubated with 
streptavidin-fluorescein isothiocyanate (FITC) (PharMingen, San Diego, CA, USA) for 
15 min at 4°C.? ? After washing 3 times with PBS, flow cytometry analysis was 
performed by a FACS scan using the CellQuest software (PharMingen). 
Measurement of soluble TRAIL and TRAIL receptor 3 in sera 
We measured the serum levels of TRAIL and TRAIL receptor 3 in CSS, asthma, and 
HES patients and in healthy volunteers before they underwent therapy.  In 11 patients 
with CSS, serum TRAIL and TRAIL receptor 3 levels were determined before therapy 
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and 3 months after the start of therapy.  TRAIL and TRAIL receptor 3 concentrations 
in sera were measured in duplicate for each sample using a commercial enzyme-linked 
immunosorbent assay (ELISA) kit (R&D Systems) according to the manufacturer’s 
protocols.  
Immunohistochemical staining for TRAIL receptor 3  
Eleven CSS patients and 8 patients with Wegener’s granulomatosis (male, 2; female, 6; 
mean age, 60.1 ± 13.1 years) were randomly selected.  The preliminary diagnosis of 
Wegener’s granulomatosis was made from clinical symptoms and confirmed by the 
existence of vasculitis in tissue biopsy.  The biopsied tissues obtained from these 
patients were examined by immunohistochemical staining for TRAIL receptor 3 using a 
goat anti-TRAIL receptor 3 polyclonal antibody (R&D Systems) and visualized by 
employing the diaminobenzidine (DAB) method as described previously (27).  Briefly, 
4-mm thick sections were mounted on poly-L-lysine-coated slides, dewaxed, and 
washed in Tris-buffered saline (pH 7.4) for 10 min.  For optimal antigen retrieval, 
sections were pressure cooked in 0.01 M citrate buffer (pH 6.0) for 90 s.  Endogenous 
peroxidase activity was blocked using a 3% hydrogen peroxide solution in methanol for 
10 min.  Following 2 washes in (PBS) with 1% saponin, the blocking reaction was 
performed.  The sections were incubated with the primary antibody solution for 2 h at 
room temperature using a 1:50 dilution of the antibody.  Negative control slides were 
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incubated with goat immunoglobulin G (IgG) (R&D Systems).  Secondary biotinylated 
anti-immunoglobulin antibody (R&D Systems) was added, and the mixture was 
incubated for 30 min at room temperature.  Following washing, the sections were 
incubated with streptavidin conjugated to horseradish peroxidase (Amersham) and then 
rinsed with deionized water.  DAB substrate solution was added and the mixture was 
incubated for 10 min.  A brown color reaction represented a positive result. 
Assay for apoptosis  
After incubation in various states, 1 × 106 eosinophils were collected and the exposure 
of phosphatidylserine was detected by flow cytometry analysis using the Annexin 
V-FITC Apoptosis Detection kit (PharMingen), as described in the previous section.  
In all experiments, apoptotic data were confirmed by terminal deoxynucleotidyl 
transferase (TdT)-mediated digoxigenin uridine triphosphate (dUTP) nick-end labeling 
(TUNEL) assay using a commercially available kit (TUNEL Label Mix; Roche 
Diagnostics), according to the manufacturer’s instructions.  
Measurement of active caspase-3 
Incubation of 1 × 107 eosinophils was done with various concentrations of TRAIL in the 
complete medium.  After the incubation, eosinophils were collected and active 
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caspase-3 levels were measured using the ELISA kit that recognizes caspase-3 zymogen 
and other active caspases, according to the manufacturer’s instructions (R&D Systems). 
51Cr release assay  
To investigate T-cell-mediated neutrophil apoptosis, we performed 51Cr release assay as 
previously described (22).  Briefly, 10 million eosinophils (target cells) were incubated 
with 100 µCi (3.7 MBq) [51Cr] sodium chromate/106 cells for 1 h and washed 5 times 
with PBS.  The labeled eosinophils (5 × 103 cells/well) were incubated with autologous 
T cells (effector cells).  Preliminarily, we performed coincubation for various durations 
of time (8, 12, 24, 36, and 48 h) and observed that 24 h of coincubation was optimal.  
After 24 h of incubation, supernatants of each well were collected and radioactivity was 
measured with a gamma counter (1480 WIZARTM 3; PerkinElmer, Downers Grove, IL, 
USA).  Specific lysis was calculated by the formula: specific 51Cr-release (%) = [(mean 
experimental cpm–mean spontaneous cpm)/(mean maximum cpm–mean spontaneous 
cpm)] × 100 in which spontaneous release represents counts per min (cpm) in 
supernatants from wells containing target cells with the medium only, and maximum 
release represents cpm in supernatants from wells containing target cells in the medium 
with 2% Triton X-100.  The data obtained from 8 of the subjects are presented as the 
mean ± standard deviation. 
Western blotting analysis  
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To determine the effect of glucocorticoids on TRAIL receptor 3, 1 × 107 eosinophils 
were incubated with glucocorticoids (500 nM) (Sigma-Aldrich Corp.) for various time 
durations.  After incubation of eosinophils, western blot analysis was performed as 
previously described (28;29).  Briefly, 1 × 107 eosinophils were collected and lysed on 
ice for 20 min in 1 mL of lysis buffer containing 50 mM 
N-(2-hydroxyethyl)piperazine-N’-2-ethanesulfonic acid (HEPES), 150 mM NaCl, 1% 
Triton X-100, 10% glycerol, and a cocktail of protease inhibitors (Roche, Indianapolis, 
IN, USA).  The lysates were spun, and the 20-µL supernatants were collected and the 
same volume, i.e., 20 µL of double-strength sample buffer (20% glycerol, 6% sodium 
dodecyl sulfate (SDS), 10% 2-mercaptoethanol) was added.  The samples were boiled 
for 10 min.  Proteins were analyzed on 10% polyacrylamide gels by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
electrophoretically to nitrocellulose membranes at 150 mA for 1 h by using a semidry 
system.  The membranes were incubated with mouse monoclonal antihuman TRAIL 
receptor 3 antibody (Clone 90903; R&D Systems), mouse monoclonal anti-human 
TRAIL receptor 1 antibody (Clone 69036; R&D Systems), or mouse antihuman actin 
monoclonal antibody (Santa-Cruz Biotechnology Inc., Santa-Cruz, CA USA) followed 
by a sheep antimouse IgG coupled with horseradish peroxidase.  Peroxidase activity 
was visualized by the Enhanced Chemiluminescence detection system (GE Healthcare , 
Little Chalfont, Bucks, UK). 
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Development of short interfering RNA (siRNA) vector against TRAIL receptor 3 
The pSUPER-retro-GFP vector was purchased from OligoEngine Japan (Tokyo, Japan), 
and TRAIL receptor 3 knockdowns were constructed in accordance with the 
manufacturer’s protocol.  The oligonucleotides were designed as follows: sense, 
5′-CAGACTCAACGCTTCCAACAATGAACC-3′; anti-sense, 
5′-GGTTCATTGTTGGAAGCGTTGAGTCTG-3′.  These were ligated into BglII and 
BamHI sites of the vector.  These vectors were transfected to packaging cells (PG-13; 
American Type Culture Collection (ATCC) and cultured in Dulbecco’s modified 
Eagle’s medium with 10% fetal bovine serum.  At 48 h after transfection, the culture 
supernatants were collected and used for further transfection.  Transfection of 1 × 106 
cells/ml eosinophils in the complete medium was achieved with TRAIL receptor 3 
siRNA according to the manufacturer’s protocol.  After 48 h of incubation, the cells 
were rinsed with PBS and used for further analysis as described above. 
Statistical Analysis  
We used one-way factorial analysis of variance (ANOVA) with the Bonferroni-Dunn 
test and the Mann-Whitney test.  For statistical analysis, StatView and MedCalc 
software were used.  Statistical significance was inferred at a value of P < 0.05.  Most 
values were expressed as mean ± standard deviation (SD) 
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Results 
Expression of TRAIL receptor on eosinophils 
For flow-cytometry analysis, we used eosinophils from 14 CSS patients (eosinophil 
count = 3893.4 ± 2317.5/µL), 11 asthma patients (eosinophil count = 610.3 ± 345.2/µL), 
7 HES patients (eosinophil count = 3652.4 ± 2432.9/µL), and 8 healthy volunteers 
(eosinophil count = 422.3 ± 267.2/µL).  As shown in Fig. 1, eosinophils from the CSS, 
asthma, and HES patients, and the healthy volunteers expressed all the TRAIL receptors 
on their surface.  With regard to TRAIL receptor 3, a decoy receptor of TRAIL, the 
TUNEL positive cell percentage was significantly higher in CSS patients compared to 
asthma and HES patients and to healthy volunteers (Fig. 1B).  The expression level of 
TRAIL receptor 4, the other decoy receptor of TRAIL, in healthy volunteers was 
significantly lower than those in the other subjects.  Contrarily, the expression level of 
TRAIL receptor 2 was significantly higher in the healthy volunteers compared to that in 
the other participants.  The expression level of TRAIL receptor 1 was higher in the 
healthy volunteers compared to those in the others; however, the difference was not 
statistically significant (Fig. 1B). 
Serum TRAIL receptor 3 levels 
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The serum TRAIL receptor 3 levels in the CSS patients were significantly higher than 
those in the asthma and HES patients and the healthy volunteers (CSS, mean ± SD, 
1155.2 ± 962.1 pg/ml; asthma, 782.4 ± 337.8 pg/ml; HES, 851.3 ± 417.7 pg/ml; healthy 
volunteers, 589.4 ± 155.5 pg/ml; Fig. 2A).  In terms of distinguishing CSS from 
asthma or HES using serum TRAIL receptor 3 level, the sensitivity and specificity were 
60.9% and 94.8%, respectively (cutoff serum TRAIL receptor 3 value = 841.9 pg/ml).  
The serum TRAIL receptor 3 levels of 11 CSS patients significantly decreased 3 months 
after the start of therapy (before, mean ± SD, 2374.0 ± 1669.9 pg/ml; after, 986.1 ± 
604.7 pg/ml; Fig. 2B).  The clinical symptoms of CSS patients improved with the use 
of glucocorticoids.  Serum TRAIL receptor 3 levels before the start of therapy 
exhibited a significant positive correlation with peripheral eosinophil counts (P < 0.05, 
r = 0.412?, but not with neutrophil counts (P = 0.912, r = –0.112) and lymphocyte 
counts (P = 0.829, r = 0.109) 
Immunohistochemical staining for TRAIL receptor 3 
The skin biopsy specimens of CSS patients demonstrated massive eosinophil infiltration 
following hematoxylin-eosin staining (Fig. 3A, 3E).  In immunohistochemical analysis 
for TRAIL receptor 3, infiltrating inflammatory cells in the lesions stained intensely 
positive for TRAIL receptor 3 (Fig. 3B, 3F).  On the contrary, the infiltrating 
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inflammatory cells observed in the renal lesions in Wegener’s granulomatosis patients 
did not stain positive for the receptor (Fig. 3D, 3H). 
Serum TRAIL levels  
To evaluate the influence of TRAIL, we investigated the serum TRAIL levels.  There 
was no significant difference in serum TRAIL levels among the 4 groups (CSS patients, 
80.7 ± 45.9 pg/ml; asthma patients, 81.6 ± 50.3 pg/ml; HES patients, 79.9 ± 44.5 pg/ml; 
healthy volunteers, 84.2 ± 40.5 pg/ml).  Moreover, no significant difference was 
observed between the serum TRAIL levels before and after therapy in the 11 CSS 
patients (before therapy, 89.6 ± 40.4 pg/ml; after therapy, 89.6 ± 40.2 pg/ml).  The 
serum TRAIL level did not reveal any significant correlation with peripheral eosinophil 
counts (P = 0.16, r = –0.242) and neutrophil counts (P = 0.06, r = 0.312); however, it 
showed significant positive correlation with lymphocyte counts (P < 0.01, r = 0.521). 
Comparison of the effect of recombinant TRAIL on eosinophil apoptosis in CSS and 
asthma patients 
To compare the effect of TRAIL on eosinophil apoptosis, we incubated eosinophils with 
various amounts of recombinant TRAIL for 12 h and investigated the apoptotic cell 
percentage.  Preliminarily, we performed incubation for various time durations (4, 8, 
12, and 18 h) or various concentrations of TRAIL (50 ng/ml, 100 ng/ml, 500 ng/ml, 1 
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µg/ml, 10 µg/ml, and 50 µg/ml); we observed that 12 h of incubation and 10 µg/ml of 
concentration are optimal.  The concentration of 10 µg/ml recombinant TRAIL 
induced apoptosis in eosinophils (Fig. 4A), and apoptotic cell percentage induced by 
TRAIL (10 µg/ml) was significantly lower in CSS patients than in asthma patients (Fig. 
4B).  The addition of a smaller amount of recombinant TRAIL (500 ng/ml, 100 ng/ml, 
and 50 ng/ml) did not induce the apoptosis of eosinophils in both groups (data not 
shown).  All apoptotic data were confirmed by TUNEL staining (data not shown). 
Additionally, we measured the level of active caspase-3, which is an intracellular 
protease in the apoptosis-induced signaling pathway activated by TRAIL.  The active 
caspase-3 concentration induced in the 1 µg/ml and 10 µg/ml concentrations of TRAIL 
was significantly lower in CSS patients than in asthma patients (Fig. 4C). 
Expression of TRAIL on lymphocytes and lymphocyte cytotoxicity against eosinophils  
Peripheral blood T cells are known to express TRAIL on their surface in atopic 
dermatitis (30) and in some autoimmune diseases such as systemic lupus erythematosus 
(22).  Moreover, in our study, we observed significant positive correlation between the 
serum TRAIL level and peripheral lymphocyte count.  Therefore, we examined 
TRAIL expression on T cells and evaluated the cytotoxicity of T cells against 
eosinophils.  T cells obtained from the CSS and asthma patients expressed TRAIL on 
their surface (Fig. 5A).  There was no significant difference in the percentage of 
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TRAIL expression between CSS patients and asthma patients (Fig. 5B).  The result of 
autologous T-lymphocyte coincubation with eosinophils is shown in Fig. 5C.  For 
incubation with a high quantity of T cells (effecter cell:target cell, 40:1 and 80:1), the 
specific 51Cr release was significantly lower in CSS patients compared to asthma 
patients. 
Influence of glucocorticoids on TRAIL receptor 3 expression by eosinophils 
To investigate the effect of glucocorticoids on the TRAIL receptor 3 expression by 
eosinophil in CSS, we incubated eosinophils from the CSS patients with glucocorticoids.  
Preliminarily, we performed incubation under various concentrations of glucocorticoids 
(10, 50, 100, 500, and 1000 nM) and observed that 500 nM is the optimal concentration.  
Glucocorticoids downregulated TRAIL receptor 3 expression by eosinophils from the 
CSS patients (Fig. 6A). 
Influence of TRAIL receptor 3 suppression in CSS eosinophils on TRAIL-induced 
apoptosis 
To evaluate the transfection efficiency, we measured the green fluorescence protein 
(GFP) positive cells in the transfected eosinophils.  As shown in Fig. 6B, transfection 
efficiency against eosinophils from the CSS patients was about 20%.  The transfection 
efficiency against eosinophils from the asthma patients was almost same as that of the 
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CSS patients.  TRAIL receptor 3 siRNA significantly inhibited the endogenous TRAIL 
receptor 3 expression on the eosinophils obtained from the CSS patients while showing 
no effect on TRAIL receptor 1 and actin expression by the eosinophils (Fig. 6C).  The 
suppression of TRAIL receptor 3 expression by siRNA significantly increased the 
TRAIL-induced apoptosis of eosinophils from the CSS patients (Fig. 6D, 6E, P < 0.05).  
The TRAIL receptor 3 suppression of eosinophils from asthma patients did not display 
any significant effect on the eosinophil apoptosis. 
Discussion 
To our knowledge, this is the first report illustrating the increased expression of TRAIL 
receptor 3, a decoy receptor of TRAIL, on eosinophils in CSS.  A previous study 
suggested that the impairment of CD95 (Apo1/Fas)-mediated apoptosis induced 
prolonged survival of eosinophils in CSS (10) , however, the detailed mechanism of 
tissue and blood eosinophilia is still unclear.  With regard to TRAIL and eosinophil 
survival, it was suggested that purified eosinophils from atopic patients revealed the 
expressions of TRAIL receptor 1, 3, and 4 surface proteins (24).  In addition, 
Robertson et al (25) reported that, in the airways after exposure to allergens, enhanced 
expression of TRAIL and TRAIL receptor 4 and decreased expression of the DRs 
(TRAIL receptors 1 and 2) on eosinophils might contribute to prolonged survival of the 
eosinophils.  In our study, the expression pattern of TRAIL receptor on eosinophils in 
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the asthma patients and healthy volunteers were almost the same as the results obtained 
by Robertson et al (25).  The expression level of TRAIL receptor 3 was significantly 
higher in the CSS patients than in the asthma and HES patients.  The TRAIL 
concentration that induced eosinophil apoptosis in asthma patients was higher than that 
reported by Robertson et al (25).  The number of autologous T-cells required to induce 
eosinophil apoptosis was high (T cell:eosinophil, 40:1).  Peripheral blood T cells are 
known to express TRAIL on their surfaces in atopic dermatitis (30) and in some 
autoimmune diseases such as systemic lupus erythematosus (22;31), which can induce 
the apoptosis of leukocytes (22).  In asthmatic patients, TRAIL is expressed in the 
airways by inflammatory cells infiltrating the bronchial mucosa, as well as by structural 
cells of the airway wall including fibroblasts and epithelial, endothelial, and smooth 
muscle cells (32).  In our study, peripheral T-cells expressed TRAIL on their surfaces 
and serum TRAIL receptor 3 levels in the CSS patients demonstrated a significant 
positive correlation with peripheral eosinophil counts; however, no such correlation was 
observed with lymphocyte and neutrophil counts and the serum levels of the receptor 
decreased in parallel with the improvement in the disease.  Immunohistochemically, 
tissue infiltrating eosinophils expressed TRAIL receptor 3 in case of CSS; however, the 
inflammatory cells infiltrating the tissues in case of the renal lesions of Wegener’s 
granulomatosis did not stain positively for TRAIL receptor 3.  Although the 
transfection effect was about 20%, the suppression of TRAIL receptor 3 expression 
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using siRNA significantly increased the TRAIL-induced apoptotic eosinophils in the 
CSS patients.  Taken together, we think that the increased expression of TRAIL 
receptor 3 might protect eosinophils from TRAIL induced apoptosis in peripheral blood 
and tissue microenvironments in case of CSS.  
Glucocorticoids are the cornerstone of CSS treatment (1;2;8).  In fact, in our study, the 
clinical symptoms improved and eosinophil count decreased with the use of 
glucocorticoids.  There are several reports concerning glucocorticoid associated 
eosinophil apoptosis.  Glucocorticoids can induce apoptosis of eosinophils but not 
neutrophils (33;34) ; they can do so via the interaction with its receptor on eosinophil 
membrane.  The existence of IL-5 affects the apoptotic effect of glucocorticoids (35).  
On the other hand, glucocorticoids enhance the recognition and engulfment of apoptotic 
eosinophils by macrophages or bronchial epithelial cells (36).  Glucocorticoids can 
also affect the chemokine production and adhesion molecules expression by eosinophils.  
Thus, glucocorticoids have multiple effects on eosinophil function.  In this study, we 
found that glucocorticoids could affect TRAIL receptor 3 expression by eosinophils 
from CSS patients.  This is a newly identified effect of glucocorticoids on the 
eosinophil molecule and might become regarded as one of the reasons for 
glucocorticoid-induced eosinophil apoptosis. 
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Successful treatment of CSS entails the differentiation of this syndrome from asthma 
and appropriate immunosuppressive therapy (1;2;8).  We found that the sensitivity and 
specificity of distinguishing CSS from asthma or HES using serum TRAIL receptor 3 
levels were 60.9% and 94.8%, respectively (cutoff serum TRAIL receptor 3 value, 
841.9 pg/ml).  Abnormal laboratory findings in patients with CSS include an increased 
peripheral blood eosinophil count and a raised erythrocyte sedimentation rate (ESR) 
(1;37).  However, it is sometimes difficult to distinguish CSS from asthma using these 
markers because of following reasons: 1) in rare cases of CSS, eosinophilia is absent 
and wide-ranging and rapid changes in eosinophil counts take place? (38); 2) use of 
corticosteroids to treat asthma may result in a failure to detect eosinophilia in patients 
with undiagnosed CSS; 3) increase in ESR occurs in other disorders such as infection.  
Other serological markers such as antineutrophil cytoplasmic antibodies are present in 
approximately 40% of CSS patients with the most common pattern being their 
perinuclear distribution (39;40).  In addition, antineutrophil cytoplasmic 
antibody-positivity needs to be confirmed by the demonstration of myeloperoxidase in 
the serum? (2).  In this study, the specificity of serum TRAIL receptor 3 was relatively 
high.  A positive result for the serum TRAIL receptor 3 might become one of the 
distinguishing markers of CSS from asthma; however, a negative result cannot preclude 
the existence of CSS because the sensitivity of the test is not so high.  In addition, all 
the CSS patients investigated in this study were in a vasculitic phase, and it is not clear 
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whether the asthma patients investigated in this study would be developing CSS in the 
future.  Little is known about the serum marker that can distinguish between asthma 
and CSS (41).    Our study was relatively small in terms of the study population and 
was of a short duration; hence, definitive conclusions cannot be drawn from the results 
obtained.  Therefore, we propose that clinical studies of longer durations and larger 
sample sizes addressing this point are necessary to judge the true diagnostic value of the 
serum TRAIL receptor 3 level. 
Some caspases have an important role in inducing TRAIL receptor-mediated apoptotic 
signaling.  TRAIL interacting with activated DR4 or DR5 can induce active caspase-8 
that initiates proapoptotic signaling cascades leading to the cleavage of cellular factors 
and transmits its proapoptotic activity to executioner caspases such as caspase-3 and -7, 
thereby inducing apoptosis (12;16;18;19;21).  Thus, caspases are key intracellular 
molecules in the regulation of apoptosis, and defects in caspase-induced apoptosis can 
cause hypereosinophilia (36).  In our study, the caspase-3 activity induced by 
recombinant TRAIL was significantly lower in the CSS patients compared to the 
asthma patients.  Impaired TRAIL-induced apoptosis signaling might have contributed 
to the eosinophilia observed in the CSS patients. 
Prominent eosinophilia is one of the defining features of CSS (38). ?  Its magnitude 
commonly reflects the clinical disease activity and, in many situations, eosinophil 
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suppression results in clinical improvement (38;42;43).?  CSS can affect virtually any 
organ system in the body (44;45), and, therefore, systemic symptoms are prominent in 
the case of CSS (1;2).  Analysis of tissue biopsy specimens from patients with CSS 
reveals an eosinophil-rich inflammatory cell infiltrate with granuloma formation in 
connective tissues and blood-vessel walls (1;2).  Eosinophils can cause tissue injury by 
releasing an array of toxic products such as eosinophil cationic protein (1;2;8).  Thus, 
eosinophils play an important role in the pathogenesis of CSS and, therefore, the 
elucidation of the mechanism of eosinophil survival in tissue microenvironment is 
necessary.  In this regard, our study provides a new insight; therefore, we think that 
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FIGURE 1.  Comparison of TNF-related apoptosis-inducing ligand (TRAIL) receptor 
expression on eosinophils of healthy volunteers and patients suffering from asthma, 
hypereosinophilia (HES), and Churg-Strauss syndrome (CSS).  Eosinophils obtained 
from each group of patients expressed all TRAIL receptors investigated in this study 
(representative data, Fig. 1A).  TRAIL receptor 3 expression level was significantly 
higher in the CSS patients compared to the others.  In the healthy volunteers, the 
expression level of TRAIL receptor 4 was significantly lower than those in the others, 
while that of TRAIL receptor 2 was significantly higher.  The expression level of 
TRAIL receptor 1 was higher in the healthy volunteers compared to the others; however, 
the difference was not statistically significant (Fig. 1B, *P < 0.01, **P < 0.05, 
Bonferroni/Dunn with a one-way factorial ANOVA). 
 
FIGURE 2.  Serum level of TNF-related apoptosis-inducing ligand (TRAIL) receptor 
3.  Serum TRAIL receptor 3 levels in Churg-Strauss syndrome (CSS) patients were 
significantly higher than those in asthma and hypereosinophilia (HES) patients and in 
healthy volunteers.  All patients were studied prior to the start of therapy.  Bars 
indicate mean values in each group (Fig. 2A, *P < 0.01, **P < 0.05, Bonferroni/Dunn 
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with one-way factorial ANOVA; s-TRAIL-R3, serum TRAIL receptor 3).  Serum 
TRAIL receptor 3 in 11 CSS patients significantly decreased 3 months after the start of 
therapy.  Bars indicate mean values in each group (Fig. 2B, **P < 0.05, 
Bonferroni/Dunn with one-way factorial ANOVA; s-TRAIL-R3, serum TRAIL receptor 
3). 
 
FIGURE 3.  Immunohistochemical analysis of TNF-related apoptosis-inducing ligand 
(TRAIL) receptor 3.  Skin biopsy specimen of Churg-Strauss syndrome (CSS) patients 
demonstrated massive infiltration of eosinophils in the lesion (hematoxylin-eosin 
staining, × 150 Fig. 3A, × 400 Fig. 3E).  Infiltrating inflammatory cells, which are 
considered to be eosinophils, are stained positive for TRAIL receptor 3 (× 150 Fig. 3B 
and × 400 Fig. 3F).  Negative control for the first antibody is shown in Fig. 3C (× 150) 
and Fig. 3G (× 400).  The infiltrating inflammatory cells in the renal lesions in 
Wegener’s granulomatosis patients were not stained positive for TRAIL receptor 3 (× 
150 Fig. 3D, × 400 Fig. 3H). 
 
FIGURE 4.  Effect of recombinant TNF-related apoptosis-inducing ligand (TRAIL) 
on eosinophil apoptosis.  Addition of 10 µg/ml recombinant TRAIL induced apoptosis 
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in eosinophils obtained from asthma patients but did not induce apoptosis in eosinophils 
acquired from Churg-Strauss syndrome (CSS) patients (Fig 4A, representative data).  
After incubation with 10 µg/ml recombinant TRAIL, the annexin V positive percentage 
was significantly higher in the asthma patients compared to the CSS patients (Fig. 4B, 
*P < 0.01, Bonferroni/Dunn with one-way factorial ANOVA).  Active caspase-3 levels 
after the incubation with 1 µg/ml and 10 µg/ml recombinant TRAIL was significantly 
higher in the asthma patients compared to the CSS patients (**P < 0.05, *P < 0.01, 
Bonferroni/Dunn with one-way factorial ANOVA). 
 
FIGURE 5.  TNF-related apoptosis-inducing ligand (TRAIL) expression on T cells 
and coincubation of eosinophils with autologous T cells.  Peripheral T lymphocytes 
from Churg-Strauss syndrome (CSS) patients expressed TRAIL on their surfaces (Fig. 
5A, representative data).  There was no significant difference in TRAIL expression 
level between CSS patients and those suffering from asthma (Fig. 5B).  Upon 
incubation with a high quantity of T cells (effecter cell:target cell = 40:1 and 80:1), the 
specific 51Cr release was significantly lower in the CSS patients than in the asthma 
patients (**P < 0.05, *P < 0.01, Bonferroni/Dunn with one-way factorial ANOVA). 
 
FIGURE 6.  Influence of glucocorticoids and siRNA against TNF-related 
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apoptosis-inducing ligand (TRAIL) receptor 3.  Incubation with 500 nM 
glucocorticoids downregulated TRAIL receptor 3 expression in eosinophils from 
Churg-Strauss syndrome (CSS) patients (Fig. 6A, representative data from 5 individual 
experiments using 5 different CSS patients; negative control was incubated with PBS).  
The transfection efficiency of siRNA against TRAIL receptor 3 was almost 20% (Fig. 
6B, representative data from 5 individual experiments using 5 different CSS patients).  
The siRNA decreased endogenous TRAIL receptor 3 expression of eosinophils from the 
CSS patients; however, it did not reveal any effect on the expressions of TRAIL 
receptor 1 and actin from eosinophils (Fig. 6C, representative data).  Suppression of 
TRAIL receptor 3 expression by siRNA significantly increased the TRAIL-induced 
apoptosis of eosinophils from the CSS patients (Fig. 6D; representative data, 6E; *P < 
0.05, n = 8, Bonferroni/Dunn with one-way factorial ANOVA).  The TRAIL receptor 3 
siRNA did not show any significant effect against the apoptosis of eosinophils from 
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